China Entry Experts CMD specializes in navigating China's NMPA and connecting Western medtech manufacturers with market access. Their end-to-end regulatory services, including registration, QMS, postmarket surveillance, and local agent representation, are delivered by a bilingual, bicultural team from offices in Boston and Beijing to help companies overcome regulatory, language, and cultural barriers and accelerate approvals.

End-to-End Support Beyond regulatory work, CMD provides CRO and market intelligence across the product lifecycle, enabling clients to move from development to launch with confidence. This integrated approach supports cross-sell opportunities for clients needing clinical trial management, overseas data acceptance, and real-world evidence, with fast access through dual-market presence.

Market Intelligence Edge Offering China market assessments and reimbursement analysis helps manufacturers tailor pricing, payer strategies, and market entry plans, reducing go-to-market risk. CMD's capability to incorporate overseas clinical data and real-world evidence can shorten regulatory timelines and improve market uptake for foreign devices entering China.

Broad Device Coverage CMD's experience spans Class I–III devices, IVDs, diagnostics, combination products, and SaMD, servicing indications across orthopedics, ophthalmology, cardiovascular, IVF, oncology, and radiology. This breadth makes CMD a versatile partner for multiple product types planning China market access.

Thought Leadership With a strong track record of success stories and ongoing free news and webinars, CMD positions itself as a trusted advisor and inbound lead source. This creates multiple touchpoints for outreach, content-led campaigns, and ongoing education to nurture prospective clients exploring China entry and regulatory compliance.